CD33 Antibodies And Use Of Same To Treat Cancer

a technology of cd33 antibodies and cancer, which is applied in the direction of antibody medical ingredients, drug compositions, peptides, etc., can solve the problem that no effective cd33-targeted treatment is currently on the mark

Inactive Publication Date: 2013-11-21
SEATTLE GENETICS INC
View PDF1 Cites 60 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0015]In one aspect, the invention provides methods of treating a patient having or at risk of having a cancer that expresses CD33, by administering to the patient an effective regime of a humanized antibody CD33 as disclosed herein. The CD33-expressing cancers include acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), acute promyelocytic leukemia (APL), chronic myelogenous leukemia (CML), chronic myelomonocytic leukemia (CMML), a chronic myeloproliferative disorders, precursor B-cell acute lymphoblastic leukemia (preB-ALL), precursor T-cell acute lymphoblastic leukemia (preT-ALL), multiple myeloma (MM), mast cell disease, and myeloid Sarcoma. The humanized antibodies are preferably administered in a pharmaceutically suit

Problems solved by technology

Although CD33 has been targeted for treatment of cancer, e.g., acute myeloid

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • CD33 Antibodies And Use Of Same To Treat Cancer
  • CD33 Antibodies And Use Of Same To Treat Cancer
  • CD33 Antibodies And Use Of Same To Treat Cancer

Examples

Experimental program
Comparison scheme
Effect test

examples

I. Generation of Anti-CD33 Antibodies

Materials

[0138]Cell lines described in the following examples were maintained in culture according to the conditions specified by the American Type Culture Collection (ATCC) (Manassas, Va.) or the Deutsche Sammlung von Mikroorganismen and Zellkulturen GmbH (DSMZ), (Braunschweig, Germany). Primary AML cells were maintained in Iscove's Modified Dulbecco's medium (IMDM) containing 20% heat-inactivated FBS, supplemented with 25 ng / ml each of granulocyte-macrophage-colony-stimulating factor (GM-CSF), granulocyte-colony-stimulating factor (G-CSF), interleukin-3 (IL-3) and stem cell factor (SCF). Cell culture reagents were obtained from Invitrogen Corp (Carlsbad, Calif.) and cytokines were purchased from PeproTech (Rocky Hill, N.J.).

Methodologies:

Saturation Binding Assays

[0139]One hundred thousand CD33-positive cells (HL-60, HEL 92.1.7, and HEK-293F cells transfected to express human or cynomologus CD33) were transferred to 96-well plates. AlexaFluor-64...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Fractionaaaaaaaaaa
Fractionaaaaaaaaaa
Cytotoxicityaaaaaaaaaa
Login to view more

Abstract

The invention provides murine, chimeric, and humanized antibodies that specifically bind to CD33. The antibodies are useful for treatment and diagnoses of various cancers as well as detecting CD33.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS[0001]This application claims the benefit of U.S. Provisional Application No. 61 / 649,110, filed May 18, 2012.BACKGROUND[0002]CD33 is a 67 kDa plasma membrane protein that binds to sialic acid and is a member of the sialic acid-binding Ig-related lectin (SIGLEC) family of proteins. CD33 is known to be expressed on myeloid cells. CD33 expression has also been reported on a number of malignant cells. Although CD33 has been targeted for treatment of cancer, e.g., acute myeloid leukemia, no effective CD33-targeted treatments are currently on the market. The present invention solves these and other problems.SUMMARY OF THE CLAIMED INVENTION[0003]Provided herein are monoclonal antibodies that specifically bind to the human CD33 protein and methods of using those antibodies to treat cancers that express the CD33 protein. The monoclonal antibodies contain complementarity determining regions (CDRs) of SEQ ID NOs:19, 20 and 21 in the heavy chain variable r...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): C07K16/28
CPCC07K16/2896A61K2039/505C07K2317/24C07K2317/33C07K2317/567C07K2317/73C07K2317/92A61K47/6851A61K31/551C07K16/2803A61P35/00A61P35/02A61P43/00A61K39/395A61K47/50C07K16/28C07K16/46Y10S530/809C07K2317/56C07K2317/565
Inventor SUTHERLAND, MAY KUNGRYAN, MAUREENSUSSMAN, DJANGOBURKE, PATRICKJEFFREY, SCOTT
Owner SEATTLE GENETICS INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap